v3.25.1
Related parties (Details)
 12 Months Ended
Dec. 31, 2024
EUR (€)
employee
item
Dec. 31, 2023
EUR (€)
item
Dec. 31, 2022
EUR (€)
Dec. 31, 2019
Nov. 06, 2019
Aug. 28, 2019
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]            
Number of executive committee members | item 4          
Number of board of directors | employee 9          
Deferred income other than contract liabilities € 1,071,352,000 € 1,327,463,000 € 1,989,230,000      
Gilead [member]            
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]            
Percentage of ownership interest 25.35%     25.84% 25.10% 22.04%
Number of Directors Represented as Board of Directors | item 2          
Minimum Percentage Of Ownership Required To Appoint Investor Board Designees 20.00%          
Trade and other payables   585,000        
Trade and other receivables € 2,268,000 5,198,000 7,877,000      
Royalties Receivable 2,200,000 2,400,000 2,600,000      
Royalties receivable relating to development of Filgotinib   2,500,000 5,100,000      
Revenue Recognized Related To The Performance Obligation For The Drug Discovery Platform 230,182,000 230,242,000 230,423,000      
Revenue Recognised Related To Filgotinib Performance Obligation 26,041,000 429,439,000 174,432,000      
Royalty income related to the commercialization of filgotinib 10,604,000 9,466,000 10,726,000      
Cost Reimbursements Recognized Related To The Development Of GLPG1690 128,000 299,000 411,000      
Cross charges from and to Gilead relating to filgotinib (4)   € 3,643,000 (2,374,000)      
included in sales and marketing expenses     31,000      
Included in research and development expenditure.     (31,000)      
Purchase of raw materials, semi-finished products and finished products of Jyseleca     13,539,000      
Number of performance obligations | item   2        
Gilead collaboration agreement for drug discovery platform | Gilead [member]            
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]            
Deferred income other than contract liabilities € 1,068,981,000 € 1,299,163,000 1,529,405,000      
Collaboration agreement for filgotinib | Gilead [member]            
Disclosure of amounts incurred by entity for provision of key management personnel services provided by separate management entities [line items]            
Deferred income other than contract liabilities   26,268,000 € 456,352,000      
Revenue That Was Included In Deferred Income At The Beginning Of The Period   € 26,300,000